

# Calcitonin effects on cartilage and fracture healing

G.P. Lyritis, P.J. Boscainos

Laboratory for the Research of the Musculoskeletal System, University of Athens, KAT Hospital, Kifissia, Greece

## Abstract

The literature about the effects of systemically administered calcitonin on fracture healing and in the prevention of disuse osteoporosis after fracture are reviewed in this study. Fracture healing is a biological process of great importance for the survival of the injured animal. Endochondral ossification is augmented in the fracture site followed by fast remodeling of the produced woven bone. There is strong evidence of the direct effects of calcitonin on cartilage proliferation as well as the vascularization of the callus. Calcitonin is found to promote the cartilaginous phase of fracture healing. On the other hand, the innervation of callus reveals an extensive distribution of sensory fibers containing a calcitonin gene-related peptide, a neuropeptide with potent vasodilatory actions. From several experimental studies, salmon calcitonin administration has been found to have a beneficial effect on fracture healing. Studies in humans also concur that calcitonin may speed up the time of fracture repair and facilitate early mobilization of the injured limb. Finally, calcitonin prevents post-fracture bone loss due to increased post-injury remodeling and lowers hydroxyproline and calcium excretion of patients who underwent internal fixation of fracture on the hip.

**Keywords:** Fracture Healing, Osteoarthritis, Internal Fixation of Fractures, Regional Osteoporosis, Calcitonin

## The effects of calcitonin on various types of cartilage

Cartilage plays a vital role in musculoskeletal function. Growth plate and secondary ossification centers are the main loci of skeletal growth, and this process follows the mechanism of endochondral ossification<sup>1</sup>. The produced intermediate cartilaginous model helps osteogenesis, forming the necessary space and secreting paracrine substances. Another type of cartilage that is also of great importance for the function of the musculoskeletal system is the articular cartilage. This kind of cartilage gives joints the necessary viscoelasticity for the attenuation of vibrations during motion and muscular function. Finally, another vital function of cartilage is callus formation. Fracture healing is accomplished through the process of endochondral ossification, except in certain cases (i.e. stable internal fixation of fractures).

The importance of calciotropic hormones in the general function of cartilaginous tissue and especially in fracture healing has not been extensively studied until now<sup>2-7</sup>.


The effect of calcitonin on the calcification of the growth plate

has been shown *in vitro* in primary cultures of chicken growth plate chondrocytes<sup>8</sup>. Calcitonin's action upon the growth plate<sup>9-12</sup> can also be studied experimentally in growing rats because the growth plate has a strong metabolic function during growth. In a rat model of growing skeleton, 40 male rats aged 5 days were treated with 0.2 IU salmon calcitonin administered subcutaneously on a daily basis, while another 40 male rats of the same age received a placebo<sup>13</sup>. The growth plate and the metaphysis of the proximal tibia were examined histologically and histomorphometrically 7, 14, 21 and 28 days from baseline. Specifically, growth plate thickness, the cell number of the columns of the reproducing zone, the animal's weight and length of the right tibia were measured. An acceleration of skeletal growth was found in animals receiving calcitonin and this was noted by the increased thickness of the growth plate, the increased cell number of the growing cartilage and the increase in tibial length (Fig. 1). These results are in accordance with other reports<sup>9,13,14</sup>.

*In vitro* studies in chondrocyte cultures using low concentrations of calcitonin (0.5%) as thyroid extract showed a more than twofold increase of cell proliferation and considerable increase of glycosaminoglycan production<sup>14</sup>. Similar results were found in the formation of the components of bone matrix, such as proteoglycans and type II collagen after treatment with calcitonin<sup>15</sup>.

The effect of calcitonin on the produced bone in the

Corresponding author: G.P. Lyritis, Laboratory for Research of the Musculoskeletal System, University of Athens, KAT Hospital, Kifissia 14561, Greece. E-mail: lyritis@ismnti.org



**Figure 1.** Changes in tibial length (mm) during the study. Calcitonin group shows increased skeletal growth in comparison with the placebo group. (Reproduced from GP Lyritis, 1983<sup>3</sup>).

metaphyseal area facilitates the development of good quality bone in the diaphysis, whereas cortical bone has a qualitatively better appearance than that observed in animals not treated with calcitonin<sup>17</sup>.

### The effects of calcitonin on articular cartilage

Considering the beneficial effect of calcitonin on the growth plate and fracture healing, it could be of great interest if we could also find some beneficial effect of that hormone on articular cartilage, especially in osteoarthritis. The relative importance of cartilage and bone changes in the initiation and progression of osteoarthritis is still being debated.


In an experimental study with rabbits which underwent cartilage destruction by different means, it has been shown that calcitonin has a protective action on cartilage which is greater than the action of anti-inflammatory drugs<sup>18</sup>. The state of hyper-metabolism, that develops in unstable joints, involves bone, synovium and articular cartilage. The increased bone turnover is likely to contribute to cartilage breakdown. In an experimental knee osteoarthritis model involving dogs, an early and sustained rise in urinary and serum bone resorption markers was observed. Calcitonin markedly reduced the levels of these markers and the severity of osteoarthritic lesions<sup>19</sup>. The longer the duration of calcitonin therapy, the lower the score of osteoarthritic lesions (Fig. 2). In a rabbit model of experimental osteoarthritis, a group of animals treated with injectable calcitonin showed a regeneration of the surface of articular cartilage, an increase of the layers of the hyaline zone and a decrease of the osteophyte formation<sup>20</sup>.

In an *in vitro* culture of chondrocytes from human osteoarthritic hips and knees, calcitonin appears to decrease collagenolytic activity and markedly stimulate attachment of chondrocytes on fibronectin<sup>21</sup>.

### The effects of calcitonin in callus innervation and vascularization

Callus vascularization plays an important role in its maturation because it contributes to the gradual replacement of cartilaginous callus by bone tissue. Paracrine substances (growth factors), such as prostaglandins, IGFs and TGF- $\beta$ , promote angiogenesis. Calcitonin gene-related peptide (CGRP) has been considered as the causative neuropeptide for callus angiogenesis<sup>22</sup>. Bone neuropeptides can act as direct regulators of osteoblastic function<sup>23</sup>. This action in fracture healing is promoted by the indirect positive response of vascular endothelium cells, monocytes and histiocytes<sup>23</sup>.

Recent experimental and clinical studies implicate bone nerves in different bone functions such as bone remodeling, fracture healing and pseudarthrosis<sup>23,24</sup>. It has been reported that intact innervation is essential for normal fracture healing because nerve injury induces a large, but mechanically insufficient, fracture callus<sup>25</sup>. An experimental study in rats with tibial fracture after sciatic nerve section showed an extensive concentration of CGRP in sensory nerve fibers of callus<sup>23</sup>. It is noticeable that CGRP has a strong vasodilative



**Figure 2.** Changes in the molar ratio of pyridoline (Pyr) / deoxypyridoline (D-Pyr) at different times after anterior cruciate ligament transection (ACLT) (upper panel) or SHAM-operation (lower panel) (Manicourt et al. 1999, with permission).

action. This way, the huge callus observed after sciatic nerve section can be explained<sup>24</sup>. Calcitonin, and such other calciotropic hormones (PTH, 1,25-(OH)<sub>2</sub>-D<sub>3</sub>), are supposed to contribute to the production of other promotive substances of bone matrix, like neutral proteases<sup>26</sup>.

### Experimental data for the effects of calcitonin on fracture healing

There are numerous experimental studies in the literature investigating the action of calcitonin on fracture healing<sup>27-43</sup>. All these studies have been done in rats or rabbits where a fracture of the peripheral skeleton was performed. The dose administered corresponds to 2-5 IU of salmon calcitonin depending on the type, age and weight of the animal. The parameters examined are the histological study of callus, calcium content, radioactive isotope retention, bone enzyme and biochemical indices of callus, as well as of serum and urine and finally, the mechanical strength of the callus.

Of the above studies, 16 examine the effect of calcitonin upon secondary (osteocartilaginous) callus formation. In 5 of these studies it was not possible to detect any beneficial effect of calcitonin on fracture healing between the animals<sup>29,32,35,39,43</sup>. In 2 other studies<sup>38,39</sup>, calcitonin was found to have an adverse effect by way of decreased collagen formation and mineralization as well as decreased callus strength.

However, in the other 9 studies<sup>27,28,30,31,34,35,36,37,41</sup> a positive effect on fracture healing was found, which is shown from the histologic appearance of callus, biochemical and immunohistochemical findings and radiological appearance. The conclusion in the majority of these studies was that calcitonin stimulates endochondral ossification during fracture healing, causing an increase in cartilaginous callus and faster maturation. The differences found<sup>29,32,35,39</sup> may be caused by inadequate<sup>29,32</sup> or very high<sup>35,39</sup> doses of calcitonin, resulting in secondary hyperparathyroidism due to hypocalcaemia.

In cases of primary fracture healing<sup>34,42</sup> without the process of endochondral ossification, calcitonin has no effect, although its administration inhibits regional osteoporosis under the materials of fixation<sup>42</sup>.

### The effects of calcitonin on fracture healing in humans

The action of calcitonin on fracture healing in humans has not been extensively studied. In some clinical studies<sup>44-46</sup>, it has been established that there is a clinical and radiological improvement in patients with recent fractures of the peripheral skeleton<sup>45</sup>, an acceleration in the formation of radiologically visible callus, and clinical improvement in Paget's disease patients with multiple fractures<sup>44</sup>.

Calcitonin has also been used in clinical settings of patients with injuries of the musculoskeletal system, such as incorporation of bone grafts after local injections of

calcitonin<sup>47</sup>, restoration of bone cysts after dental extractions<sup>48</sup> and an improvement in delayed fracture healing after local administration of calcitonin in patients with neglected fractures<sup>49</sup>. Finally, the analgesic effect of calcitonin (Fig. 3) in patients with recent osteoporotic vertebral fractures<sup>50</sup> is of great importance.


### The effects of calcitonin on regional and immobilization osteoporosis

Immobilization is one of the main causes of disuse or regional osteoporosis. The pathogenesis of immobilization osteoporosis is multifactorial, but the main cause is bone unloading from mechanical strains. Immobilization is very common in fractures and usually lasts for a long period. Bone loss in these cases is extensive and fast<sup>51-53</sup>. Recovery from bone loss due to disuse is in most cases gradually achieved after the return of the usual mechanical loadings. In cases where this is not possible, it is advisable to add antiresorptive drugs. Calcitonin seems to be effective in partially reversing this bone loss<sup>51-54</sup>.

Fracture regional osteoporosis is a specific form of immobilization osteoporosis found at the site of the fracture and periarticular regions near the fracture. Osteoporosis is the result not only of immobilization but also of vasomotor disorders. Osteoporosis found after fracture and immobilization for a long period of time in plaster especially affects the metaphyseal regions and carpal and tarsal bones<sup>55</sup>.

Following the internal fixation of fractures with metal plates and screws, without immobilization in plaster, local osteoporosis is found under the metal plate<sup>55</sup>. This type of osteoporosis is due to the stress-shielding phenomenon as well as the local endosteal and periosteal vascular damage.

Calcitonin partially inhibits osteoporosis under the plate<sup>42,56</sup> and improves the mechanical properties of experimental osteotomies<sup>57</sup>. It has been found that, apart from the mechanical improvement in the region of the osteotomy,



**Figure 3.** Pain rating (VAS scale) in the standing position. Calcitonin-treated patients can be mobilized from 14th day of the study.

there is an improvement in the mechanical parameters of the non-affected leg. This finding supports the effectiveness of calcitonin in bone microarchitecture.

Finally, it is important to note the effect of calcitonin administration for the prevention of post-surgical bone loss, especially in patients with hip fractures<sup>58</sup>. This effect is confirmed with the reduction of hydroxyproline/creatinine and calcium/creatinine ratios. In elderly patients with fractures, calcitonin administration immediately after surgery is of great clinical importance as it accelerates fracture healing, prevents disuse or regional osteoporosis and promotes faster mobilization of patients due to its analgesic effect.

In a prospective clinical study on the effect of 200 IU nasal salmon calcitonin administered daily for a period of three months in patients with a recent hip fracture, it was found that calcitonin protected the bone loss in the non-fractured hip after the end of the three month period of calcitonin treatment<sup>59</sup>. This beneficial effect on the bone of the femoral neck remained statistically significant after the discontinuation of the treatment.

### Effect of calcitonin on the mechanical properties of bone

In the rabbit a higher fracture load and stiffness is observed after calcitonin treatment for 12 weeks (6 IU daily)<sup>56</sup>. Moreover, in the lumbar spine of retired breeder female ovariectomized Wistar rats, improvement in stiffness values and load-bearing capacity is a lot greater with combined administration of salmon calcitonin (10 µg/kg five times per week) and hPTH (1-38) (100 µg/kg five times per week)<sup>60</sup>.

In ovariectomized ewes, torsional strength and stiffness on torsion of the femur was significantly improved, using 50 or 100 IU doses of calcitonin<sup>61</sup>. This phenomenon was not dose-dependent and differences in the parameters studied were not statistically significant. On the other hand, ultimate compressive stress was significantly improved in a dose-related response in the calcitonin group.

There are only a few animal model studies investigating the effect of calcitonin on mechanical properties of bone. No clinical studies have been published on this issue and further research is justified from the already existing results.

### Conclusions

Systemically administered calcitonin interacts with cartilage and musculoskeletal trauma to a significant degree. Calcification of the growth plate and an acceleration of skeletal growth is evident in experimental studies with animals receiving calcitonin. Moreover, calcitonin seems to reduce the severity of osteoarthritic lesions on the articular cartilage of animals with experimental osteoarthritis. Cartilaginous callus maturation seems to increase in experimental studies using calcitonin, although further research on appropriate doses is required. Data from human

studies on the effects of calcitonin on musculoskeletal trauma in humans are scarce. There are indications of clinical and radiological improvement of trauma patients receiving calcitonin, with special reference to pain and immobilization osteoporosis. These encouraging results call for more clinical studies on the effects of calcitonin on musculoskeletal trauma.

---

### References

1. Glowacki J, Deftos L. The effects of calcitonin on cartilage growth. In: Pecile A (ed). Calcitonin. Elsevier Science Publishers, Amsterdam; 1985:205-211.
2. Meller H, Meller Y, Kestenbaum RS, Shany S, Galinsky D, Zuili I, Yankovitch N, Giat J, Conforti A, Torok G. Parathormone, calcitonin and vitamin D metabolites during normal fracture healing in geriatric patients. Clin Orthop 1985; 199:272-279.
3. Lindholm TS. Effects of 1 $\alpha$ -vitamin D on osteoporotic changes induced by calcium deficiency in bone fractures in adult rats. J Trauma 1982; 18:336.
4. Lindholm TS, Sevasticoglou JA. The effect of 1 $\alpha$ -vitamin D on healing of experimental fractures in adult rats. Acta Orthop Scand 1978; 49:485-491.
5. Lindgren JU, DeLuca HF, Mazess RB. Effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> on bone tissue in the rabbit: Studies on fracture healing, disuse osteoporosis and prednisone osteoporosis. Calcif Tissue Int 1984; 36:591-595.
6. Dodds RA, Catterall A, Bitensky L, Chayen J. Abnormalities in fracture healing induced by vitamin B6 deficient rats. Bone 1986; 7:489-495.
7. Crabb ID, O'Keefe RJ, Puzas E, Rosier RN. Differential effects of parathyroid hormone on chick growth plate and articular chondrocytes. Calcif Tissue Int 1992; 50:61-66.
8. Ishikawa Y, Wu LN, Genge BR, Mwale F, Wuthier RE. Effects of calcitonin and parathyroid hormone on calcification of primary cultures of chicken growth plate chondrocytes. J Bone Miner Res 1997; 12:356-366.
9. Burch WM, Corda G. Calcitonin stimulates maturation of mammalian growth plate cartilage. Endocrinology 1985; 116:1724-1728.
10. Kawashima K, Iwata S, Endo H. Growth stimulative effect of PTH calcitonin and N<sub>6</sub>,O<sub>2</sub>-dibutyryl adenosine 3',5'-cyclic monophosphoric acid on chick embryonic cartilage cultivated in a chemically defined medium. Endocrinol Jpn 1980; 27:349-356.
11. Kato Y, Shumazu A, Nakashima K, Suzuki F, Jikko A, Iwamoto M. Effects of PTH and calcitonin on alkaline phosphatase activity and matrix calcification in rabbit growth plate chondrocyte cultures. Endocrinology 1990; 127:114-118.
12. Glowacki J, Deftos LJ. The effects of calcitonin on cartilage growth. In: Pecile A (ed). Calcitonin. Elsevier Science Publishers, Amsterdam; 1985:105-211.
13. Lyritis GP. The effect of salmon calcitonin on the epiphyseal plate and the metaphyseal osteogenesis of the

- rat. *Prog Clin Biol Res* 1985; 187:225-232.
14. Pazzaglia UE, Zatti G, Di Nucci A, Coci A. Inhibitory effect of salmon calcitonin on bone resorption: morphological study of the tibial growth plate in rats. *Calcif Tissue Int* 1993; 52:125-129.
  15. Jones DG, Smith RL. Stimulation of adult chondrocyte metabolism by a thyroid-derived factor. *J Orthop Res* 1990; 8:227-233.
  16. Franchimont P, Bassleer C. Effects of hormones and local growth factors on articular chondrocyte metabolism. *J Rheumatol Suppl* 1991; 27:68-70.
  17. Giardino R, Fini M, Aidini NN, Gnudi S, Biagini G, Gandolfi MG, Mongiorgi R. Calcitonin and alendronate effects on bone quality in osteoporotic rats. *J Bone Miner Res* 1996; 13:335.
  18. Badurski JE, Schwamm W, Popko J, Zimnoch L, Rogowski F, Pawlica J. Chondroprotective action of salmon calcitonin in experimental arthropathies. *Calcif Tissue Int* 1991; 49:27-34.
  19. Manicourt DH, Altman RD, Williams JM, Devogelaer JP, Druetz-Van Egeren A, Lenz ME, Piertyla D, Thonar EJ. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. *Arthritis Rheum* 1999; 42:1159-1167.
  20. Papaioannou N, Krallins N, Khaldi L, Skarantavos Gr, Lyritis GP. Calcitonin inhibits evolution of osteoarthritic lesions. An experimental study in rabbits. 9<sup>th</sup> Transactions of the European Orthopaedic Research Society 1999; p O 40.
  21. Hellio MP, Peschard MJ, Cohen C, Richard M, Vignon E. Calcitonin inhibits phospholipase A2 and collagenase activity of human osteoarthritic chondrocytes. *Osteoarthritis Cartilage* 1997; 5:121-128.
  22. Konttinen Y, Imai S, Suda A. Neuropeptides and the puzzle of bone remodeling. State of the art. *Acta Orthop Scand* 1996; 67:632-639.
  23. Hukkanen M, Konttinen YT, Santavirta S, Nordsletten L, Madsen JE, Almaas R, Oestreicher AB, Rootwelt T, Polak JM. Effect of sciatic nerve section on neural ingrowth into the rat tibial fracture callus. *Clin Orthop* 1995; 311:247-257.
  24. Bjurholm A, Kreicbergs A, Dahlberg L, Schultzberg M. The occurrence of neuropeptides at different stages of DBM-induced heterotopic bone formation. *Bone Miner* 1990; 10:95-107.
  25. Madsen JE, Hukkanen M, Aune AK, Basran I, Moller JF, Polak JM, Nordsletten L. Fracture healing and callus innervation after peripheral nerve resection in rats. *Clin Orthop* 1998; 351:230-240.
  26. Einhorn TA, Majeska RJ. Neutral proteases in regenerating bone. *Clin Orthop* 1991; 262:286-297.
  27. Ewald F, Tachdjian MO. The effect of thyrocalcitonin on fractured humeri. *Surg Gynecol Obstet* 1967; 125:1075-1080.
  28. Tarsoly E, Bucher O. Histologische und enzymhistochemische untersuchung der callusbildung nach langdauernder calcitoninverabreichung an ratten. *Acta Chir Acad Sci Hung* 1973; 14:171-183.
  29. Harris JM III, Bean DA, Banks HH. Effect of phosphate supplementation thyrocalcitonin and growth hormone on strength of fracture healing. *Surg Forum* 1975; 26:519-521.
  30. Kolar J, Babicky J, Blahos J. Influence of 25-hydroxycalciferol and calcitonin on experimental fractures. *Acta Chir Orthop Traumatol* 1979; 46:193-199.
  31. Kolar J, Babicky A, Blahos J, Pavlik L. The influence of calcitonin and cortisone on experimental fractures. *Acta Chir Orthop Traumatol* 1975; 42:255-262.
  32. Bethge JF, Babayan R, Borm HP, von Fehrentheil R, ten Hoff H, Hose H, Mangels P, Piening H, Reimers C, Wider U. Verschung der biochemischen Beninefussung der frakturheilung in tierexperiment. *Res Exp Med* 1979; 175:197-222.
  33. Delling G, Schafer A, Ziegler R. The effect of calcitonin on fracture healing and ectopic bone formation in the rat. In: Taylor S, Foster O (ed) *Calcitonin 1969*. Proceedings of the Second International Symposium. William Heineman Medical Books, London; 1970:175-181.
  34. Schatzker J, Chapman M, Ha'Eri GB, Fornasier VL, Sumner-Smith G, Williams C. The effect of calcitonin on fracture healing. *Clin Orthop* 1979; 141:303-306.
  35. Lindgren JU, Narechania RG, McBeath AA, Lange TA. Effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> and calcitonin on fracture healing in adult rats. *Clin Orthop* 1981; 160:304-308.
  36. Falter EW, Hellerer O, Aigner R, Bruckner WL. Klinisch-chemische serumbefundenach experimenteller frakturstruzung und calcitonin behandlung. *Langenbecks Arch Chir* 1982; 356:71-76.
  37. Lyritis G, Manolakis H, Bitounis B, Badras L, Ioannidis Th. Mitsou A. The effect of salmon calcitonin on fracture healing in rats. Proceedings 7th International Congress of Orthopaedics. Rome 1982; 313-314.
  38. Ekeland A, Muhre L, Underdal T. Effects of salmon calcitonin on mechanical properties of healing and intact bone and skin in rats. *Acta Orthop Scand* 1983; 54:462-469.
  39. Ekeland A, Underdal T. Effects of salmon calcitonin on synthesis and mineralization of collagen in rats. *Acta Orthop Scand* 1983; 54:760-767.
  40. Ekeland A, Gautvic KM, Underdal T. Calcitonin producing tumour. Effects of fracture repair and stromal bone in rats. *Acta Orthop Scand* 1983; 54:760-767.
  41. Lyritis G, Badras L. The effect of salmon calcitonin on primary and secondary fracture healing. IX International Conference of ICCRH, Nice, pp. 1986.
  42. Lyritis G, Badras L, Ioannidis Th. Effect of salmon calcitonin on primary fracture healing. *Acta Orthop Hellenica* 1986; 37:10-15.
  43. Paavolainen P, Taivainen T, Michelsson JE, Lalla M, Penttinen R. Calcitonin and fracture healing. An experimental study on rats. *J Orthop Res* 1989; 100-106.
  44. Verinder DGR, Burke J. The management of fractures in Paget's disease of bone. *Injury* 1980; 10:276-280.
  45. Calistri A. La calcitonina in ortopedia e traumatologia.

- C1 Terap 1982; 100:613-619.
46. Melanotte PL, Caira S. Salmon calcitonin effect in proximal femur fracture repair in elderly patients. *Curr Ther Res* 1986; 39:449-454.
  47. Knize DM. The influence of periosteum and calcitonin on onlay bone graft survival. *Plast Reconstr Surg* 1974; 53:190-199.
  48. Foster SC, Kronman JH. The effects of topical thyrocalcitonin on extraction sites in the jaws of dogs. *Oral Surg Med Oral Pathol* 1974; 38:866-873.
  49. De Bastiani G. Local effects of calcitonin in bone calcification. In: Pecile A (ed) *Calcitonin 1980*, *Excerpta Medica Int Cong Ser* 540, 1981; 307-313.
  50. Lyritis GP, Tsakalagos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A double blind placebo-controlled clinical study. *Calcif Tissue Int* 1991; 49:369-372.
  51. Hayashi T, Yamamuro T, Okumura H, Kasai R, Tada K. Effect of eel calcitonin on the prevention of osteoporosis induced by combination of immobilization and ovariectomy in the rat. *Bone* 1989; 10:25-28.
  52. Shimuzu T, Ishoguro N, Miura T. The effect of calcitonin on osteoporosis of the rat hind limb induced by denervation and isograft transplantation. *J Reconstr Microsurg* 1992; 8:41-45.
  53. Orimo H, Fujita T, Yoshikawa M. Effect of calcitonin on the development of immobilization osteoporosis in rats: *Endocrinol Jpn* 1971; 18:117-121.
  54. Minaire P, Mallet E. Immobilization bone loss: preventive effect of calcitonin in several clinical models. In: Christiansen C, Johansen JS, Riis (eds) *Osteoporosis 1987, Int Symp on Osteoporosis 2*, Osteopress, Copenhagen; 1987:762-766.
  55. Lyritis GP, Karanasos Th, Ioannidis Th, Soucacos P. Regional osteoporosis of the ankle. Changes of some radiological indices following immobilization in a cast. *Acta Orthop Hellenica* 1983; 34:279-283.
  56. Karachalios T, Giannarakos DG, Papanikolaou G, Lyritis GP. Does calcitonin affect the secondary regional osteoporosis under the materials of internal fixation of fractures? *Osteoporosis 1990*, Christiansen C, Overgaard K, (eds). 1990; 1665-1666.
  57. Karachalios T, Lyritis GP, Giannarakos D, Papanikolaou G, Sotopoulos C. Calcitonin effects on rabbit bone. Bending test on ulnar osteotomies. *Acta Orthop Scand* 1992; 63:615-618.
  58. Tsakalagos N, Magiasis B, Tsekoura M, Lyritis G. The effect of short-term calcitonin administration on biochemical bone markers in patients with acute immobilization following hip fracture. *Osteoporosis Int* 1993; 3:337-340.
  59. Kaloudis IA, Karachalios Th, Roidis NT, Bargiotas A, Katsiri MG, Lyritis GP. The effect of daily administration of 200 IU of nasal calcitonin on biochemical bone markers, bone density and the risk of contralateral hip fracture in patients with recent intertrochanteric. *J Bone Miner Res* 1999; 14:S77.
  60. Mosekilde L, Danielsen CC, Gasser J. The effect of vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone (1-38), and combination therapy, assessed in aged ovariectomized rats. *Endocrinology* 1994; 134:2126-2134.
  61. Geusens P, Boonen S, Nijs J, Jiang Y, Lowet G, Van Audekercke R, Huyghe C, Caulin F, Very JM, Dequeker J. Effect of calcitonin on femoral bone quality in adult ovariectomized ewes. *Calcif Tissue Int* 1996; 59:315-320.